Jade Biosciences, Inc. Net Income
Jade Biosciences, Inc. (JBIO) reported Net Income of -$55.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-10
- Jade Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$55.77M.
- Jade Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$40.37M.
- Jade Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$31.93M.
- Jade Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$25.18M.
- Jade Biosciences, Inc. net income (loss) attributable to parent for fiscal 2025 was -$127.41M.
- Jade Biosciences, Inc. net income (loss) attributable to parent for fiscal 2024 was -$69.63M.
- Jade Biosciences, Inc. net income (loss) attributable to parent for fiscal 2023 was -$75.52M.
- Jade Biosciences, Inc. net income (loss) attributable to parent for fiscal 2022 was -$51.51M.
| Period end | Net Income (Loss) Attributable to Parent 0 month | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$55.77M 10-Q · filed 2026-08-10 | -$96.13M 10-Q · filed 2026-08-10 | -$128.06M derived: sum of 3 quarters · filed 2026-08-10 | -$153.24M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$40.37M 10-Q · filed 2026-08-10 | -$72.30M derived: sum of 2 quarters · filed 2026-08-10 | -$97.47M derived: sum of 3 quarters · filed 2026-08-10 | -$129.61M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$31.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$57.11M derived: sum of 2 quarters · filed 2026-03-06 | -$89.24M derived: sum of 3 quarters · filed 2026-08-10 | -$127.41M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | -$25.18M 10-Q · filed 2025-11-14 | -$57.31M derived: sum of 2 quarters · filed 2026-08-10 | -$95.48M 10-Q · filed 2025-11-14 | -$125.59M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | -$32.13M 10-Q · filed 2026-08-10 | -$70.30M 10-Q · filed 2026-08-10 | -$100.42M derived: sum of 3 quarters · filed 2026-08-10 | -$117.28M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$38.17M 10-Q · filed 2026-08-10 | -$2.52M 10-Q · filed 2025-04-25 | -$68.28M derived: sum of 2 quarters · filed 2026-08-10 | -$85.15M derived: sum of 3 quarters · filed 2026-08-10 | -$109.92M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2024-12-31 | -$30.11M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | -$46.98M 10-K · filed 2026-03-06 | -$71.75M derived: sum of 3 quarters · filed 2026-03-06 | -$69.63M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | -$16.28M 10-Q · filed 2025-11-14 | -$16.24M 10-Q · filed 2024-11-12 | -$41.64M derived: sum of 2 quarters · filed 2025-11-14 | -$64.20M 10-Q · filed 2024-11-12 | -$85.24M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$590.00K 10-Q · filed 2025-11-14 | -$24.77M 10-Q · filed 2024-11-12 | -$47.96M 10-Q · filed 2024-08-12 | -$68.37M derived: sum of 3 quarters · filed 2025-04-25 | -$87.94M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | -$23.19M 10-Q · filed 2025-04-25 | -$43.60M derived: sum of 2 quarters · filed 2025-04-25 | -$63.16M derived: sum of 3 quarters · filed 2025-04-25 | -$82.19M derived: sum of 4 quarters · filed 2025-04-25 | ||
| 2023-12-31 | -$20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$39.98M derived: sum of 2 quarters · filed 2025-03-27 | -$59.00M derived: sum of 3 quarters · filed 2025-03-27 | -$75.52M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$19.56M 10-Q · filed 2024-11-12 | -$38.59M derived: sum of 2 quarters · filed 2024-11-12 | -$55.11M 10-Q · filed 2024-11-12 | -$70.13M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$19.02M 10-Q · filed 2024-11-12 | -$35.55M 10-Q · filed 2024-08-12 | -$50.57M derived: sum of 3 quarters · filed 2024-11-12 | -$64.16M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-03-31 | -$16.52M 10-Q · filed 2024-11-12 | -$31.54M derived: sum of 2 quarters · filed 2024-11-12 | -$45.13M derived: sum of 3 quarters · filed 2024-11-12 | -$57.12M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2022-12-31 | -$15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$28.61M derived: sum of 2 quarters · filed 2024-03-25 | -$40.60M derived: sum of 3 quarters · filed 2024-03-25 | -$51.51M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | -$13.59M 10-Q · filed 2023-11-13 | -$25.58M derived: sum of 2 quarters · filed 2023-11-13 | -$36.49M 10-Q · filed 2023-11-13 | -$44.71M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | -$11.99M 10-Q · filed 2023-11-13 | -$22.90M 10-Q · filed 2023-08-14 | -$31.12M derived: sum of 3 quarters · filed 2023-11-13 | -$37.31M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-03-31 | -$10.91M 10-Q · filed 2023-11-13 | -$19.13M derived: sum of 2 quarters · filed 2023-11-13 | -$25.32M derived: sum of 3 quarters · filed 2023-11-13 | -$31.09M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2021-12-31 | -$8.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$14.41M derived: sum of 2 quarters · filed 2023-03-29 | -$20.18M derived: sum of 3 quarters · filed 2023-03-29 | -$22.96M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | -$6.18M 10-Q · filed 2022-11-14 | -$11.96M derived: sum of 2 quarters · filed 2022-11-14 | -$14.74M 10-Q · filed 2022-11-14 | -$18.41M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$5.78M 10-Q · filed 2022-11-14 | -$8.56M 10-Q · filed 2022-08-15 | -$12.22M derived: sum of 3 quarters · filed 2022-11-14 | -$14.53M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-03-31 | -$2.78M 10-Q · filed 2022-11-14 | -$6.45M derived: sum of 2 quarters · filed 2022-11-14 | -$8.75M derived: sum of 3 quarters · filed 2022-11-14 | -$10.96M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2020-12-31 | -$3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$5.97M derived: sum of 2 quarters · filed 2022-03-30 | -$8.18M derived: sum of 3 quarters · filed 2022-03-30 | -$9.61M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | -$2.31M 10-Q · filed 2021-11-15 | -$4.51M derived: sum of 2 quarters · filed 2021-11-15 | -$5.95M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$2.20M 10-Q · filed 2021-11-15 | -$3.64M 10-Q · filed 2021-08-16 | ||||
| 2020-03-31 | -$1.44M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |